INFI - インフィニティ・ファ―マシュ―ティカルズ （Infinity Pharmaceuticals Inc.） インフィニティ・ファ―マシュ―ティカルズINFIのチャート
INFIの企業情報
| symbol | INFI |
|---|---|
| 会社名 | Infinity Pharmaceuticals Inc （インフィニティ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 インフィニティ・ファーマシューティカルズ(Infinity Pharmaceuticals Inc.)は創薬・新薬開発会社。同社の主力製品は同社が血液悪性腫瘍と炎症性疾患において研究しているクラスI ･PI3K- デルタとPI3K- ガンマの強力な経口阻害剤である。同社のretaspimycin塩酸塩(HCl)は熱ショック蛋白質90(Hsp90)の強力な選択的阻害剤である。ホスホイノシチド3 - キナーゼ(PI3K)は中心ノードとして細胞表面受容体から下流の生化学的事象へ信号を伝達する重要な細胞信号伝達蛋白質である。同社のこのプログラムにおける主力開発候補は臨床試験が行われた、血液悪性腫瘍と炎症性疾患を形成するクラスI PI3K-デルタ･ガンマの強力な経口阻害剤IPI-145である。血液悪性腫瘍は血液･骨髄の癌であり、慢性リンパ性白血病（CLL）、ホジキンリンパ腫、非ホジキンリンパ腫（NHL）などの白血病とリンパ腫を含む。 インフィニティ・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。主力製品候補のIPI-145は血液悪性腫瘍と炎症性疾患を対象とする、ホスホイノシチド3-キナ―ゼ（PI3K）のクラスIデルタとガンマアイソフォ―ムの経口阻害剤である。またIPI-443などを参考に、第二のPI3K製品候補、PI3Kデルタとガンマの経口阻害剤を開発。 Infinity Pharmaceuticals, Inc. ('Infinity' or the 'Company'), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. |
| 本社所在地 | 784 Memorial Drive Cambridge MA 02139 USA |
| 代表者氏名 | Adelene Q. Perkins アデリーンQ.パーキンス |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 617-453-1000 |
| 設立年月日 | 34759 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 22人 |
| url | www.infi.com |
| nasdaq_url | https://www.nasdaq.com/symbol/infi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -32.06800 |
| 終値（lastsale） | 2.45 |
| 時価総額（marketcap） | 139283842.6 |
| 時価総額 | 時価総額（百万ドル） 144.96890 |
| 売上高 | 売上高（百万ドル） 6.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 95.80390 |
| 当期純利益 | 当期純利益（百万ドル） 43.64100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Infinity Pharmaceuticals Inc. revenues was not reported. Net loss decreased 40% to $16.4M. Lower net loss reflects Other expense decrease from $6.9M (expense) to $0K Other General and administrative decrease of 44% to $5.5M (expense) Stock Based compensation in General and decrease of 46% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to -$0.31. |
INFIのテクニカル分析
INFIのニュース
Infinity Pharmaceuticals (INFI) Stock: Waiting For A Deal 2022/09/08 15:18:50 Seeking Alpha
Infinity Pharmaceuticals'' primary drug showed encouraging results, but company is waiting on a collaboration deal. Read here for an investment analysis on INFI.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Share Price Rebounds 69.74% From The Lows – But Can It Keep Going? 2022/09/03 16:00:00 Marketing Sentinel
In last trading session, Infinity Pharmaceuticals Inc. (NASDAQ:INFI) saw 0.34 million shares changing hands with its beta currently measuring 2.04. Company’s recent per share price level of $1.52 trading at $0.02 or 1.33% at ring of the bell on the day assigns it a market valuation of $148.60M. That closing price of INFI’s stock is … Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Share Price Rebounds 69.74% From The Lows – But Can It Keep Going? Read More »
What Do Analysts Think About Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) Future? 2022/08/24 16:10:00 Stocks Register
The trading price of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) floating higher at last check on Wednesday, August 24, closing at $1.59, 2.58% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $1.29 and $1.57. In examining the 52-week price action we see that … What Do Analysts Think About Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) Future? Read More »
A stock that deserves closer examination: Infinity Pharmaceuticals Inc. (INFI) 2022/08/23 14:08:00 US Post News
As of Monday, Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) stock closed at $1.34, down from $1.46 the previous day. While Infinity Pharmaceuticals Inc. has underperformed by -8.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INFI fell by -55.63%, with highs and lows ranging from $3.89 to $0.46, […]
Jones Trading Downgrades Infinity Pharmaceutical to Hold 2022/08/12 20:47:01 Investing.com
https://www.investing.com/news/pro/jones-trading-downgrades-infinity-pharmaceutical-to-hold-432SI-2871671
What Do Analysts Think About Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) Future? 2022/08/24 16:10:00 Stocks Register
The trading price of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) floating higher at last check on Wednesday, August 24, closing at $1.59, 2.58% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $1.29 and $1.57. In examining the 52-week price action we see that … What Do Analysts Think About Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) Future? Read More »
A stock that deserves closer examination: Infinity Pharmaceuticals Inc. (INFI) 2022/08/23 14:08:00 US Post News
As of Monday, Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) stock closed at $1.34, down from $1.46 the previous day. While Infinity Pharmaceuticals Inc. has underperformed by -8.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INFI fell by -55.63%, with highs and lows ranging from $3.89 to $0.46, […]
Jones Trading Downgrades Infinity Pharmaceutical to Hold 2022/08/12 20:47:01 Investing.com
https://www.investing.com/news/pro/jones-trading-downgrades-infinity-pharmaceutical-to-hold-432SI-2871671
US stock market closes higher, Dow Jones gains 1.63% 2022/08/11 03:43:48 InstaForex
At the close of the New York Stock Exchange, the Dow Jones rose 1.63% to a 3-month high, the S&P 500 rose 2.13% and the NASDAQ Composite rose 2.89%. The leading performer among the components of the Dow Jones index today was Walt Disney Company, which gained 4.30 points or 3.98% to close at 112.43. Salesforce.com Inc rose 6.37 points or 3.50% to close at 188.61. Goldman Sachs Group Inc rose 11.29 points or 3.35% to close at 347.91. The losers were Merck & Company Inc, which shed 0.33 points (0.37%) to end the session at 89.19. UnitedHealth Group Incorporated was down 0.46 points (0.09%) to close at 537.72, while Walmart Inc was up 0.27 points (0.21%) to close at 129. fourteen. Among the gainers among the components of the S&P 500 in today''s trading were Norwegian Cruise Line Holdings Ltd, which rose 11.82% to 13.53, Royal Caribbean Cruises Ltd, which gained 9.74% to close at 41. 67, as well as shares of Carnival Corporation, which rose 9.19% to end the session at 10.34. The biggest losers were CME Group Inc, which shed 2.24% to close at 198.40.
Infinity Pharma stock gains ~24% on survival analysis data for a phase 2 trial, Q2 results 2022/08/10 16:17:05 Seeking Alpha
Shares of micro-cap clinical-stage biotech Infinity Pharmaceuticals (INFI) jumped 24.3% to $0.92 in Wednesday mid-day trading, after it announced data from a two-year analysis of an…
How Infinity Pharmaceuticals Inc. (NASDAQ: INFI) Could Be A Loss Maker Since It Is Down -46.67% YTD? 2022/04/02 12:00:00 Marketing Sentinel
During the last session, Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s traded shares were 0.76 million, with the beta value of the company hitting 2.07. At the end of the trading day, the stock’s price was $1.20, reflecting an intraday gain of 5.26% or $0.06. The 52-week high for the INFI share is $3.89, that puts it down … How Infinity Pharmaceuticals Inc. (NASDAQ: INFI) Could Be A Loss Maker Since It Is Down -46.67% YTD? Read More »
Infinity Pharmaceuticals stock soars 25% after FY21 revenue beat 2022/03/30 16:38:06 Seeking Alpha
Shares of biotechnology company Infinity Pharmaceuticals <> soar as much as 28% a day after reporting better-than-expected FY revenue, helped by higher royalties.Company posts…
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2021 Results - Earnings Call Transcript 2022/03/30 01:30:19 Seeking Alpha
Infinity Pharmaceuticals GAAP EPS of -$0.53 in-line, revenue of $1.86M beats by $0.16M 2022/03/29 20:12:07 Seeking Alpha
Infinity Pharmaceuticals press release (INFI): FY GAAP EPS of -$0.53 in-line.Revenue of $1.86M (+8.8% Y/Y) beats by $0.16M.Total cash, cash equivalents and available-for-sale…
Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights 2022/03/29 20:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2021 financial results and provided corporate highlights. “Based on the strength and breadth of eganelisib’s activity across mTNBC and mUC as well as ovarian cancer, SCCHN, and melanoma, we raised $92 million in early